Objective:

To analyze the clinical effect of remifentanil combined with propofol in anesthesia for patients with traumatic brain injury.

Approach:

• Study Design: Retrospective analysis of medical records of 110 TBI patients treated from January 2024 to December 2024, divided into a study group (remifentanil + propofol) and a control group (propofol only).
• Monitoring Parameters: Vital signs, anesthesia efficacy, VAS scores, RSAS scores, GCS scores, and stress response levels were monitored.

Key Findings:

• No significant differences in general data between the two groups (P > 0.05).
• Lower incidence rates of agitation, stress response, and respiratory/circulatory depression in the study group (P < 0.05).
• Higher successful intubation rate in the study group (P < 0.05).
• VAS and RSAS scores at 12 h and 24 h post-medication were significantly lower in the study group (P < 0.05).
• Lower norepinephrine and angiotensin II levels at extubation in the study group (P < 0.05).
• No significant difference in GCS scores between the two groups during follow-up (P > 0.05).

Interpretation:

The study confirms that remifentanil combined with propofol has significant clinical effects in anesthesia for TBI patients, effectively alleviating perioperative pain and agitation while reducing stress responses.

Limitations:

• Single-center study may limit generalizability.
• Retrospective design may introduce bias.

Conclusion:

Remifentanil combined with propofol is effective in managing anesthesia for TBI patients, warranting clinical promotion.